首页> 美国卫生研究院文献>Journal of Transplantation >New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
【2h】

New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database

机译:在活供体与已故供体肝移植受者中的新发糖尿病:UNOS / OPTN数据库分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

New onset diabetes after transplantation (NODAT) occurs less frequently in living donor liver transplant (LDLT) recipients than in deceased donor liver transplant (DDLT) recipients. The aim of this study was to compare the incidence and predictive factors for NODAT in LDLT versus DDLT recipients. The Organ Procurement and Transplant Network/United Network for Organ Sharing database was reviewed from 2004 to 2010, and 902 LDLT and 19,582 DDLT nondiabetic recipients were included. The overall incidence of NODAT was 12.2% at 1 year after liver transplantation. At 1, 3, and 5 years after transplant, the incidence of NODAT in LDLT recipients was 7.4, 2.1, and 2.6%, respectively, compared to 12.5, 3.4, and 1.9%, respectively, in DDLT recipients. LDLT recipients have a lower risk of NODAT compared to DDLT recipients (hazard ratio = 0.63 (0.52–0.75), P < 0.001). Predictors for NODAT in LDLT recipients were hepatitis C (HCV) and treated acute cellular rejection (ACR). Risk factors in DDLT recipients were recipient male gender, recipient age, body mass index, donor age, donor diabetes, HCV, and treated ACR. LDLT recipients have a lower incidence and fewer risk factors for NODAT compared to DDLT recipients. Early identification of risk factors will assist timely clinical interventions to prevent NODAT complications.
机译:在活供体肝移植(LDLT)接受者中,发生新的移植后糖尿病(NODAT)的频率低于在已故供体肝移植(DDLT)接受者中。这项研究的目的是比较LDLT和DDLT接受者NODAT的发生率和预测因素。从2004年到2010年,对器官采购和移植网络/器官共享联合网络数据库进行了审查,其中包括902名LDLT和19,582名DDLT非糖尿病患者。肝移植后1年,NODAT的总发生率为12.2%。移植后第1、3和5年,LDLT接受者的NODAT发生率分别为7.4%,2.1%和2.6%,而DDLT接受者分别为12.5%,3.4%和1.9%。与DDLT接受者相比,LDLT接受者的NODAT风险更低(危险比= 0.63(0.52-0.75),P <0.001)。 LDLT接受者NODAT的预测因素是丙型肝炎(HCV)和治疗的急性细胞排斥反应(ACR)。 DDLT接受者的危险因素是接受者男性,接受者年龄,体重指数,供体年龄,供体糖尿病,HCV和治疗过的ACR。与DDLT接受者相比,LDLT接受者的NODAT发生率更低,危险因素更少。及早发现危险因素将有助于及时的临床干预,以预防NODAT并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号